|drug2072||NA-831 and Atazanavir Wiki||1.00|
|drug1070||Drug: NA-831 Wiki||1.00|
|drug2073||NA-831and Dexamethasone Wiki||1.00|
|D012141||Respiratory Tract Infections NIH||0.17|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This study is designed to evaluate a potential mechanism by which a hyperactive immune response may contribute to death from SARS-CoV-2; by an excessive neutrophil-mediated deposition of cell-free DNA in neutrophil extracellular traps (NET). Excessive amounts of NETs can increase rigidity of mucus, clog airways, and be agents for the development of acute respiratory distress (Narasaraju et al., Am J Pathol. 2011). Many aspects of this pathway have been observed in severe SARS-CoV-2 (Zhang et al., Respiratory research. 2020). Dornase alfa (DNAse I; Pulmozyme (Genentech) is a nebulized drug that works by degrading cell-free DNA and thus promoting airway clearance and recovery. The investigators hypothesize that by thinning mucus and degrading these NETs further lung damage may be prevented and a reduction in time to recovery may occur. The two aims of the study are to see if inhaled/nebulized dornase alfa will improve clinical outcome measures in SARS-CoV-2 related acute respiratory distress syndrome (ARDS) and to see if dornase alfa reduces the amount of bronchoalveolar lavage and blood markers of NET activity. The study will recruit patients who are on mechanical ventilation for respiratory failure related to SARS-CoV-2 positive infection and have ARDS based upon Berlin criteria. The investigators aim to recruit 20 patients for this study.
Description: Daily evaluation of PaO2/FiO2 ratio on the day prior to starting therapy and then repeat daily for 14 days after starting therapy.Measure: Improvement in PaO2/FiO2 Time: 14 days
Description: Daily evaluation of static lung compliance, measured by change in driving pressure over volume delivered, on the day prior to starting therapy and then repeated daily for 14 days after the first dose of therapy.Measure: Change in static lung compliance Time: 14 days
Description: Number of days on mechanical ventilationMeasure: Duration of mechanical ventilation Time: From date of randomization until extubation or date of death from any cause, whichever came first, assessed up to 12 months
Description: Number of days in the medical intensive care untiMeasure: Length of ICU stay Time: From date of randomization until discharge/transfer out of the ICU or date of death from any cause, whichever came first, assessed up to 12 months
Description: Number of days as an inpatient at the University of MissouriMeasure: Length of hospitalization Time: From date of randomization until discharge from acute care hospital or date of death from any cause, whichever came first, assessed up to 12 months
Description: Determination of secondary bacterial infections based upon positive culture results and clinical diagnosis by treating physician.Measure: Secondary bacterial infections Time: From date of randomization until first positive culture or clinical diagnosis of infection if occurs, assessed up to 3 months
Description: All cause mortalityMeasure: Mortality Time: Evaluation at 30 and 90 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports